Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by dismal
prognosis. Although SCLC may initially respond well to platinum-based chemotherapy, it …

Background Adjuvant therapy with durvalumab, with or without tremelimumab, may have
efficacy in patients with limited-stage small-cell lung cancer who do not have disease …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor
prognosis. Initial responses to standard-of-care chemo-immunotherapy are, unfortunately …

Ethnopharmacological relevance With high mortality and morbidity rates, lung cancer (LC)
has become one of the major threats to human health. The treatment strategies for LC …

Purpose: RB1 mutations and loss of retinoblastoma (Rb) expression represent consistent
but not entirely invariable hallmarks of small cell lung cancer (SCLC). The prevalence and …

Lung cancer is the most malignant human cancer worldwide, also with the highest incidence
rate. However, small-cell lung cancer (SCLC) accounts for 14% of all lung cancer cases …

Background No targeted drugs are currently available against small cell lung cancer
(SCLC). BCL-2 family members are involved in apoptosis regulation and represent …

Lung cancer has a significant incidence among the population and, unfortunately, has an
unfavourable prognosis in most cases. The World Health Organization (WHO) classifies lung …

Introduction Preclinical studies have demonstrated increased efficacy with combined DNA
damage response inhibition and immune checkpoint blockade compared with either alone …